ArticleImmunologic research2026
Using B-cell-targeting drugs to achieve marked efficacy in anti-signal recognition particle myopathy: two case reports.
Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Anti-signal recognition particle (anti-SRP) antibody-associated myopathy is a severe immune-mediated necrotizing myopathy characterized by elevated serum creatine kinase (CK), rapidly progressive proximal weakness, and specific pathological features on muscle biopsy. Cardiac involvement and even paralysis may occur in some patients. Response to steroid monotherapy and conventional immunosuppressants is often suboptimal, whereas B-cell-targeted therapies represent the potential advantages. We report two patients with anti-SRP myopathy treated with B-cell-targeted drugs individually. One achieved remission with low-dose rituximab (RTX), and the other responded to telitacicept (RC-18) at the lowest effective dose. During follow-up, both patients improved substantially and maintained long-term remission without relapse or infection. These cases support the feasibility of individualized B-cell-targeted strategies, including low-dose RTX and RC-18, for anti-SRP myopathy. Given the limited evidence, prospective studies are needed to assess the efficacy and safety.
Indexed as
Identifiers
41906052What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.